{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T04:48:13Z","timestamp":1679028493890},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1670","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved deucravacitinib (Sotyktu \u2013 BMS), an oral tyrosine kinase 2 (TYK2) inhibitor, for once-daily treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Deucravacitinib is the first selective TYK2 inhibitor to be approved in the US for any indication.<\/jats:p>","DOI":"10.58347\/tml.2023.1670b","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T15:50:26Z","timestamp":1678981826000},"page":"29-31","source":"Crossref","is-referenced-by-count":0,"title":["Deucravacitinib (Sotyktu) for Plaque Psoriasis"],"prefix":"10.58347","volume":"65","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2023,2,20]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T15:50:26Z","timestamp":1678981826000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1670b"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":0,"journal-issue":{"issue":"1670","published-online":{"date-parts":[[2023,2,20]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2023.1670b","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]}}}